Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip K Knop

Showing results (61-70 of 434) with videos related to

Pageof 44
Sort By:
Clinical Chemistry|March 22, 2017
Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy ControlsDavid P Sonne, Dijana Terzic, Filip K Knop, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2024
Letter: Bif195 for aspirin-induced gastric mucosal damage - More to do in further research. Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2024
Editorial: The microbiome and gastric mucosal protection in aspirin users-Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Expert Opinion on Pharmacotherapy|August 23, 2021
Treatment of type 2 diabetes in children: what are the specific considerations?Magnus F G Grøndahl, Jesper Johannesen, Kurt Kristensen, et al.
Current Diabetes Reports|October 29, 2017
Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?Magnus F Grøndahl, Damien J Keating, Tina Vilsbøll, et al.
Current Opinion in Molecular Therapeutics|December 15, 2010
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetesEspen Jimenez-Solem, Mette H Rasmussen, Mikkel Christensen, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 28, 2010
Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetesKristine J Hare, Tina Vilsbøll, Jens J Holst, et al.
Medical Hypotheses|October 5, 2011
Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?Annesofie Faurschou, Claus Zachariae, Lone Skov, et al.
Diabetes, Obesity & Metabolism|October 18, 2022
Semaglutide for the treatment of overweight and obesity: A reviewNatasha Chidekel Bergmann, Melanie J Davies, Ildiko Lingvay, et al.
Documenta Ophthalmologica. Advances in Ophthalmology|December 27, 2011
Electroretinography in healthy subjects in relation to systemic glucocorticoid intakePer Kappelgaard, Katrine B Hansen, Tina Vilsbøll, et al.
Pageof 44

Showing results (61-70 of 434) with videos related to

Sort By:
Pageof 44
Clinical Chemistry|March 22, 2017
Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy ControlsDavid P Sonne, Dijana Terzic, Filip K Knop, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2024
Letter: Bif195 for aspirin-induced gastric mucosal damage - More to do in further research. Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2024
Editorial: The microbiome and gastric mucosal protection in aspirin users-Authors' replyNina Løn, Sara Engel, Anders Damholt, et al.
Expert Opinion on Pharmacotherapy|August 23, 2021
Treatment of type 2 diabetes in children: what are the specific considerations?Magnus F G Grøndahl, Jesper Johannesen, Kurt Kristensen, et al.
Current Diabetes Reports|October 29, 2017
Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?Magnus F Grøndahl, Damien J Keating, Tina Vilsbøll, et al.
Current Opinion in Molecular Therapeutics|December 15, 2010
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetesEspen Jimenez-Solem, Mette H Rasmussen, Mikkel Christensen, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 28, 2010
Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetesKristine J Hare, Tina Vilsbøll, Jens J Holst, et al.
Medical Hypotheses|October 5, 2011
Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?Annesofie Faurschou, Claus Zachariae, Lone Skov, et al.
Diabetes, Obesity & Metabolism|October 18, 2022
Semaglutide for the treatment of overweight and obesity: A reviewNatasha Chidekel Bergmann, Melanie J Davies, Ildiko Lingvay, et al.
Documenta Ophthalmologica. Advances in Ophthalmology|December 27, 2011
Electroretinography in healthy subjects in relation to systemic glucocorticoid intakePer Kappelgaard, Katrine B Hansen, Tina Vilsbøll, et al.
Pageof 44